Abstract
Prevention and treatment of bleeding in patients suffering from hemophilia A are inconvenient due to repeated intravenous infusions owing to the short half-life of coagulation factor VIII (FVIII) in circulation. Besides (glyco-)pegylation of the FVIII molecule, a bioengineering approach comprises the protein fusion to Fc-immunoglobulin (Ig)G that mediate protection from clearance or degradation via binding to the neonatal Fc receptor. While human-like N-glycosylation of recombinant FVIII is known to be crucial for the clotting factor’s quality and function, the particular glycosylation of the fused Fc portion has not been investigated in detail so far, despite its known impact on Fcγ receptor binding. Here, we analyzed the N-glycosylation of the Fc part of a chimeric FVIII-Fc protein compared to a commercial IgG1 purified from human plasma. Fc parts from both samples were released by enzymatic cleavage and were subsequently separated via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Corresponding protein bands were referred to PNGase F in-gel digestion in order to release the respective N-glycans. Analysis via matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry revealed structural differences of both N-glycan patterns. Labeling with 2-aminobenzamide (2AB) and analysis via hydrophilic interaction liquid chromatography (HILIC) allowed a quantitative comparison of the respective N-glycosylation. Observed variations in Fc glycosylation of the chimeric FVIII fusion protein and human plasma-derived IgG1, e.g., regarding terminal sialylation, are discussed, focusing on the impact of the clotting factor’s properties, most notably its binding to Fcγ receptors.
Highlights
Hemophilia A is a hereditary blood coagulation disorder caused by the functional deficiency of endogenous clotting factor VIII (FVIII)
Prevention and treatment of bleeding in patients suffering from hemophilia A are inconvenient due to repeated intravenous infusions owing to the short half-life of coagulation factor VIII (FVIII) in circulation
N-glycosylation analysis of a chimeric human FVIII protein was performed with respect to its fragment crystallizable (Fc) fusioNn -pgalyrtcoasnydladtiiornecatlnyalcyosmispoafraedchtiomtehreicFhcupmoarntioFnVINII-gplryoctaeninpwroasfilpeeroffocrmomedmwericthialreIsgpGe1ctptouriitfsieFdc ffruosmionhupamrtananpdladsimreactslyercvoinmgpaasreadrteofetrheenFcce pcoonrttiroonl Nth-rgoluygcahnouptrothfielewohf ocolemwmoerrkc.ial IgG1 purified from human plasma serving as a reference control throughout the whole work
Summary
Hemophilia A is a hereditary blood coagulation disorder caused by the functional deficiency of endogenous clotting factor VIII (FVIII). In order to reduce the frequency of injections, considerable efforts have been made to prolong the half-life of coagulation factor concentrates. In this regard, main bioengineering strategies include chemical conjugation of polyethylene glycol to FVIII or the generation of recombinant fusion constructs of the clotting factor with human plasma proteins such as serum albumin or immunoglobulin (Ig)G [3]. Main bioengineering strategies include chemical conjugation of polyethylene glycol to FVIII or the generation of recombinant fusion constructs of the clotting factor with human plasma proteins such as serum albumin or immunoglobulin (Ig)G [3] The latter one is an established technology already applied to several therapeutic protein drugs [4]. It mainly comprises the fusion of the constant fragment crystallizable (Fc) domain of human IgG to a target protein enabling its binding to the neonatal Fc receptor (FcRn) [5] and facilitating the molecule’s recycling
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
